Home » Market News » DirectorsTalk Highlights » Shortage of drug is forcing US hospitals to stop treating patients with immune disorders
Immupharma Plc

Shortage of drug is forcing US hospitals to stop treating patients with immune disorders

A shortage of a versatile medicine used to treat immune disorders has forced US hospitals to stop treatment for many patients. 

Hospitals have begun rationing the immunoglobulin drugs (IG), prioritising patients that are most at risk of death if they go without. 

IG is used to treat immune disorders such as lupus, myositis and Guillain-Barre syndrome. 

Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.